Press Conferences

Further progress in Oncology

  • 03 August 2009
    Further progress in Oncology

    Media information: Oncology Pipeline progresses further

    News/ Information: Important milestone achieved with oncology compounds:
    • Progress of Boehringer Ingelheim's lead oncology compounds, BIBW 2992 (Tovok™) and BIBF 1120 (Vargatef™)
    • New Trial, "LUX-LUNG III", investigates Tovok™ as potential first line treatment for lung cancer patients with a particular oncogenomic footprint, an EGFR mutation.
    Website:

    Boehringer Ingelheim in oncology: Update from WCLC

Congress Overview

News & Information

Speakers

Speakers Background information for medical media outside the US only
Prof. James Spicer
Senior Lecturer, Cancer Studies Division, King’s College London, and Consultant in Medical Oncology, Guy’s and St. Thomas’ Foundation Hospital NHS Trust, London, UK
Prof. James Spicer

Prof. James Spicer is Senior Lecturer in the Cancer Studies Division of King’s College London, and Honorary Consultant in Medical Oncology at Guy’s and St Thomas’ Foundation Hospital NHS Trust.

Dr Rolf Kaiser
International Medical Project Leader for Phase I–III studies in Oncology, Boehringer Ingelheim, Biberach, Germany
Dr Rolf Kaiser

Dr Rolf Kaiser has received several awards for teaching and research during his career, including the Antiemetic Research Award from the Multinational Association of Supportive Care in Cancer (MASCC) in 2003 for his work in exploring the role of pharmacogenetics in emesis. His research has been extensively published in a range of leading international peer-reviewed journals, including the Journal of Clinical Oncology and The Lancet Oncology.

Images

Images & Videos
Videos
Images: Further progress in Oncology
  • Signal Transduction: BIBW 2992 (Tovok™ ) irreversibly block the growth factor receptor
    Signal Transduction: BIBW 2992 (Tovok™ ) irreversibly block the growth factor receptor
  • Angiogenesis: Vessels invading the tumor transport oxigen and nutrition
    Angiogenesis: Vessels invading the tumor transport oxigen and nutrition
  • Angiogenesis Inhibition: Vessels degenerate or withdraw from tumor
    Angiogenesis Inhibition: Vessels degenerate or withdraw from tumor
  • Signal transduction: a ligand binds to a growth factor receptor and initiates growth signalling cascade
    Signal transduction: a ligand binds to a growth factor receptor and initiates growth signalling cascade
  • A tumor needs oxigen and nutrition to grow
    A tumor needs oxigen and nutrition to grow
  • The EGFR/Her2 Receptor Family
    The EGFR/Her2 Receptor Family
  • Laboratory work in Research and Development
    Laboratory work in Research and Development
  • R&D Laboratory Work
    R&D Laboratory Work

Media Contact

  • Boehringer Ingelheim GmbH
    Julia Meyer-Kleinmann
    Head Science & Technology Communications
    55216 Ingelheim am Rhein
    Germany
     
    Phone +49 / 6132 / 77 8271
    Fax +49 / 6132 / 77 66 01
    Contact

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

Subscribe to RSS Feed